Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...

Amgen shares fell sharply on Monday afternoon after the company released results from a weight-loss trial that showed that ...

Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its ...

Shares of Amgen (AMGN) fell on Monday after announcing that its weight-loss drug will move into a phase 3 trial, with ...

Amgen shares are trading lower Monday afternoon. The company released full results from part one of its phase two study of ...

Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...

Amgen Inc. ( NASDAQ: AMGN) Special Call (IR Call) Conference June 23, 2025 5:30 PM ET Justin Claeys - Vice President of Investor Relations James Bradner - Executive Vice President of Research & ...

Amgen's weight-loss drug MariTide had a successful Phase 2 trial so the company is expanding development plans to study its use for heart disease and sleep apnea.

Amgen (NASDAQ:AMGN) today announced full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate subcutaneously ...

Amgen's experimental drug MariTide shows potential for significant weight loss in obese patients, despite notable side ...

Amgen's experimental obesity drug MariTide showed promising weight loss results with fewer side effects, according to a ...

Amgen is expanding development plans for its weight-loss drug MariTide to study its use for heart disease and sleep apnea.